Recently stock market analysts have updated their consensus ratings on shares of Asterias Biotherapeutics, Inc. (AST). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

04/25/2016 – Rodman & Renshaw began new coverage on Asterias Biotherapeutics, Inc. giving the company a “buy” rating. They now have a USD 12 price target on the stock.

11/18/2015 – FBR Capital Markets began new coverage on Asterias Biotherapeutics, Inc. giving the company a “outperform” rating. They now have a USD 10 price target on the stock.

05/06/2015 – Lake Street began new coverage on Asterias Biotherapeutics, Inc. giving the company a “buy” rating. They now have a USD 22 price target on the stock.

02/27/2015 – Asterias Biotherapeutics, Inc. was upgraded to “buy” by analysts at MLV & Co. They now have a USD 9 price target on the stock.

Asterias Biotherapeutics, Inc. has a 50 day moving average of 4.49 and a 200 day moving average of 4.25. The stock’s market capitalization is 166.75M, it has a 52-week low of 2.36 and a 52-week high of 12.98.

The share price of the company (AST) was down -0.67%, with a high of 4.48during the day and the volume of Asterias Biotherapeutics, Inc. shares traded was 34986.

View other investors thoughts on Asterias Biotherapeutics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.